Viral Hepatitis Market

Market Overview:

The 7 major viral hepatitis markets are expected to exhibit a CAGR of 2.69% during 2024-2034.

The viral hepatitis market has been comprehensively analyzed in IMARC's new report titled "Viral Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Viral hepatitis refers to a group of infectious diseases that primarily affect the liver and are caused by different viruses, including hepatitis A, B, C, D, and E. These viruses can result in inflammation and damage to the liver, leading to a range of symptoms and potential long-term complications. Some of the common indications are fatigue, loss of appetite, nausea, vomiting, abdominal pain, jaundice, etc. Many patients may also experience dark urine, pale stools, muscle and joint aches, a general feeling of unwellness, etc. Chronic hepatitis may not cause noticeable symptoms initially but can lead to long-term liver damage, cirrhosis, and an increased risk of liver cancer. The diagnosis of viral hepatitis involves a combination of clinical evaluation, laboratory tests, and medical history assessment. Blood tests are essential for detecting specific viral markers, including antibodies, antigens, viral genetic material, etc. Various imaging modalities, such as ultrasound, CT scans, MRI, etc., may be used to assess liver health and detect any complications. Additionally, liver biopsy or non-invasive methods, including elastography and serum biomarkers, may be performed to evaluate liver fibrosis or monitor disease progression.

The increasing cases of ingesting contaminated food or water, coupled with the growing prevalence of poor sanitation and inadequate hygiene practices, are primarily driving the viral hepatitis market. In addition to this, the rising incidence of exposure to infected blood or other body fluids through the sharing of contaminated needles or syringes, sexual contact, mother-to-child transmission during childbirth, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiviral medications, such as nucleotide analogs and interferon-alpha, for suppressing viral replication and preventing complications associated with the ailment is further bolstering the market growth. Apart from this, the inflating application of liver-supportive drugs, including hepatoprotective agents like milk thistle extract, to improve liver health, enhance liver cell regeneration, and minimize inflammation is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nucleic acid testing (NAT), since it allows the direct detection and quantification of viral RNA or DNA in blood samples and is particularly useful in diagnosing acute hepatitis, determining viral load, and assessing disease progression, is expected to drive the viral hepatitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the viral hepatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for viral hepatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the viral hepatitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the viral hepatitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the viral hepatitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current viral hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the viral hepatitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the viral hepatitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the viral hepatitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of viral hepatitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of viral hepatitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of viral hepatitis by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of viral hepatitis by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with viral hepatitis across the seven major markets?
• What is the size of the viral hepatitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of viral hepatitis?
• What will be the growth rate of patients across the seven major markets?

Viral Hepatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for viral hepatitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the viral hepatitis market?
• What are the key regulatory events related to the viral hepatitis market?
• What is the structure of clinical trial landscape by status related to the viral hepatitis market?
• What is the structure of clinical trial landscape by phase related to the viral hepatitis market?
• What is the structure of clinical trial landscape by route of administration related to the viral hepatitis market?